Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
Conclusion
In patients undergoing CA for AF, the use of uninterrupted oral rivaroxaban was feasible and event rates were similar to those for uninterrupted VKA therapy.
Name of the Trial Registry
Clinicaltrials.gov trial registration number is NCT01729871.
Source: European Heart Journal - Category: Cardiology Authors: Cappato, R., Marchlinski, F. E., Hohnloser, S. H., Naccarelli, G. V., Xiang, J., Wilber, D. J., Ma, C.-S., Hess, S., Wells, D. S., Juang, G., Vijgen, J., Hugl, B. J., Balasubramaniam, R., De Chillou, C., Davies, D. W., Fields, L. E., Natale, A., on behalf Tags: Atrial fibrillation Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Heart | Heart Attack | Ischemic Stroke | Stroke | Vitamin K | Vitamins